Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1985 May 1;161(5):1097–1111. doi: 10.1084/jem.161.5.1097

Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen

PMCID: PMC2187599  PMID: 2580934

Abstract

In raising murine hybridoma antibodies against Epstein-Barr virus (EBV)- induced membrane antigens (MA), we found one antibody that blocked the release of infectious EBV from cultured P3HR-1 cells. This monoclonal antibody (mAb) recognized a 200 kD, phosphonoacetic acid-sensitive (late) MA, and did not directly neutralize virus without complement. When this mAb was added to 33 degrees C-cultured, spontaneously EBV- producing P3HR-1 cells, the intracellular expression of viral capsid antigen and infectious virus was not inhibited, but the appearance of infectious virus in the culture medium was significantly reduced. The duration of this suppression was dependent upon the concentration of the mAb, an effect being observed to a 1:4 X 10(5) titer of the ascites mAb preparation. A more acute effect of suppression of EBV release was observed in a second model of 12-o-tetradecanoyl phorbol-13-acetate and n-butyrate induction of EBV in 37 degrees C-cultured P3HR-1 cells. Again, intracellular infectious virus production was not inhibited, but the level of infectious virus in the culture medium was significantly reduced as early as 1 and 2 d of culture with antibody. This effect was reversed within 31 h after replacement of mAb-containing medium with fresh medium. This description of antibody-mediated inhibition of EBV release might lead to the characterization of another form of immune defense for the control of EBV infections.

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edson C. M., Thorley-Lawson D. A. Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences. J Virol. 1981 Jul;39(1):172–184. doi: 10.1128/jvi.39.1.172-184.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ernberg I., Klein G., Kourilsky F. M., Silvestre D. Differentiation between early and late membrane antigen on human lymphoblastoid cell lines infected with Epstein-Barr virus. I. Immunofluorescence. J Natl Cancer Inst. 1974 Jul;53(1):61–65. doi: 10.1093/jnci/53.1.61. [DOI] [PubMed] [Google Scholar]
  3. FOLEY G. E., LAZARUS H., FARBER S., UZMAN B. G., BOONE B. A., MCCARTHY R. E. CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. Cancer. 1965 Apr;18:522–529. doi: 10.1002/1097-0142(196504)18:4<522::aid-cncr2820180418>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  4. Gergely L., Klein G., Ernberg I. Appearance of Epstein-Barr virus-associated antigens in infected Raji cells. Virology. 1971 Jul;45(1):10–21. doi: 10.1016/0042-6822(71)90107-3. [DOI] [PubMed] [Google Scholar]
  5. Henle W., Henle G., Zajac B. A., Pearson G., Waubke R., Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science. 1970 Jul 10;169(3941):188–190. doi: 10.1126/science.169.3941.188. [DOI] [PubMed] [Google Scholar]
  6. Hinuma Y., Konn M., Yamaguchi J., Wudarski D. J., Blakeslee J. R., Jr, Grace J. T., Jr Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol. 1967 Oct;1(5):1045–1051. doi: 10.1128/jvi.1.5.1045-1051.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hinuma Y., Matsumoto M., Sairenji T. Modulation of Epstein-Barr virus release from cells by components of normal human serum. J Gen Virol. 1980 Jul;49(1):197–201. doi: 10.1099/0022-1317-49-1-197. [DOI] [PubMed] [Google Scholar]
  8. Hoffman G. J., Lazarowitz S. G., Hayward S. D. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980 May;77(5):2979–2983. doi: 10.1073/pnas.77.5.2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jondal M. Antibody-dependent cellular cytotoxicity (ADCC) against Epstein-Barr virus-determined membrane antigens. I. Reactivity in sera from normal persons and from patients with acute infectious mononucleosis. Clin Exp Immunol. 1976 Jul;25(1):1–5. [PMC free article] [PubMed] [Google Scholar]
  10. King J., Laemmli U. K. Polypeptides of the tail fibres of bacteriophage T4. J Mol Biol. 1971 Dec 28;62(3):465–477. doi: 10.1016/0022-2836(71)90148-3. [DOI] [PubMed] [Google Scholar]
  11. Klein G., Svedmyr E., Jondal M., Persson P. O. EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer. 1976 Jan 15;17(1):21–26. doi: 10.1002/ijc.2910170105. [DOI] [PubMed] [Google Scholar]
  12. Luka J., Kallin B., Klein G. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology. 1979 Apr 15;94(1):228–231. doi: 10.1016/0042-6822(79)90455-0. [DOI] [PubMed] [Google Scholar]
  13. Matsumoto M., Tada Y., Yamaguchi J., Sairenji T., Hinuma Y. Further studies on inhibition of Epstein-Barr virus release by bovine serum: partial purification and characterization of the inhibitor. J Natl Cancer Inst. 1980 Feb;64(2):353–358. doi: 10.1093/jnci/64.2.353. [DOI] [PubMed] [Google Scholar]
  14. Miller G., Heston L., Hoffman G. Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody. Infect Immun. 1982 Sep;37(3):1028–1031. doi: 10.1128/iai.37.3.1028-1031.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Miller G., Lipman M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Acad Sci U S A. 1973 Jan;70(1):190–194. doi: 10.1073/pnas.70.1.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mueller-Lantzsch N., Georg-Fries B., Herbst H., zur Hausen H., Braun D. G. Epstein-Barr virus strain- and group-specific antigenic determinants detected by monoclonal antibodies. Int J Cancer. 1981 Sep 15;28(3):321–327. doi: 10.1002/ijc.2910280311. [DOI] [PubMed] [Google Scholar]
  17. Mueller-Lantzsch N., Yamamoto N., zur Hausen H. Analysis of early and late Epstein-Barr virus associated polypeptides by immunoprecipitation. Virology. 1979 Sep;97(2):378–387. doi: 10.1016/0042-6822(79)90348-9. [DOI] [PubMed] [Google Scholar]
  18. North J. R., Morgan A. J., Epstein M. A. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. Int J Cancer. 1980 Aug;26(2):231–240. doi: 10.1002/ijc.2910260216. [DOI] [PubMed] [Google Scholar]
  19. PULVERTAFT J. V. A STUDY OF MALIGNANT TUMOURS IN NIGERIA BY SHORT-TERM TISSUE CULTURE. J Clin Pathol. 1965 May;18:261–273. doi: 10.1136/jcp.18.3.261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. PULVERTAFT J. V. CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA). Lancet. 1964 Feb 1;1(7327):238–240. doi: 10.1016/s0140-6736(64)92345-1. [DOI] [PubMed] [Google Scholar]
  21. Pearson G. R., Orr T. W. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens. J Natl Cancer Inst. 1976 Mar;56(3):485–488. doi: 10.1093/jnci/56.3.485. [DOI] [PubMed] [Google Scholar]
  22. Pope J. H., Horne M. K., Scott W. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer. 1968 Nov 15;3(6):857–866. doi: 10.1002/ijc.2910030619. [DOI] [PubMed] [Google Scholar]
  23. Qualtiere L. F., Chase R., Pearson G. R. Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein. J Immunol. 1982 Aug;129(2):814–818. [PubMed] [Google Scholar]
  24. Qualtiere L. F., Chase R., Vroman B., Pearson G. R. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein. Proc Natl Acad Sci U S A. 1982 Jan;79(2):616–620. doi: 10.1073/pnas.79.2.616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sairenji T., Hinuma Y. Assay of Epstein-Barr virus by immunofluorescence. Gan. 1973 Dec;64(6):633–636. [PubMed] [Google Scholar]
  26. Sairenji T., Hinuma Y. Inhibitory effect of adult bovine serum on release of infectious Epstein-Barr virus from a virus-carrier cell line. J Natl Cancer Inst. 1975 Aug;55(2):339–343. [PubMed] [Google Scholar]
  27. Sairenji T., Hinuma Y., Sekizawa T., Yoshida M. Appearance of early and late components of Epstein-Barr virus-associated membrane antigen in Daudi cells superinfected with P3HR-1 virus. J Gen Virol. 1978 Jan;38(1):111–120. doi: 10.1099/0022-1317-38-1-111. [DOI] [PubMed] [Google Scholar]
  28. Sairenji T., Sullivan J. L., Humphreys R. E. Complement-dependent, Epstein-Barr virus-neutralizing antibody appearing early in the sera of patients with infectious mononucleosis. J Infect Dis. 1984 May;149(5):763–768. doi: 10.1093/infdis/149.5.763. [DOI] [PubMed] [Google Scholar]
  29. Seto J. T., Rott R. Functional significance of sialidose during influenza virus multiplication. Virology. 1966 Dec;30(4):731–737. doi: 10.1016/0042-6822(66)90178-4. [DOI] [PubMed] [Google Scholar]
  30. Strnad B. C., Schuster T., Klein R., Hopkins R. F., 3rd, Witmer T., Neubauer R. H., Rabin H. Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen. J Virol. 1982 Jan;41(1):258–264. doi: 10.1128/jvi.41.1.258-264.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Theofilopoulos A. N., Perrin L. H. Lysis of human cultured lymphoblastoid cells by cell-induced activation of the properdin pathway. Science. 1977 Mar 4;195(4281):878–880. doi: 10.1126/science.402691. [DOI] [PubMed] [Google Scholar]
  33. Thorley-Lawson D. A. Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells. Cell. 1979 Jan;16(1):33–42. doi: 10.1016/0092-8674(79)90185-5. [DOI] [PubMed] [Google Scholar]
  34. Thorley-Lawson D. A., Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307–5311. doi: 10.1073/pnas.77.9.5307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Thorley-Lawson D. A., Poodry C. A. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol. 1982 Aug;43(2):730–736. doi: 10.1128/jvi.43.2.730-736.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Yonemura K., Sairenji T., Hinuma Y. Inhibitory effect of 1-beta-D-arabinofuranosylthymine on synthesis of Epstein-Barr virus. Microbiol Immunol. 1981;25(6):557–563. doi: 10.1111/j.1348-0421.1981.tb00057.x. [DOI] [PubMed] [Google Scholar]
  37. zur Hausen H., O'Neill F. J., Freese U. K., Hecker E. Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature. 1978 Mar 23;272(5651):373–375. doi: 10.1038/272373a0. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES